North America Expansion Hytest is actively strengthening its North America presence with new hires in 2026, signaling a growth-focused sales opportunity to grow regional account management, direct customer engagement, and local support for diagnostic partnerships.

New HIV Antigen Launch of HIV-1 antigen Cat. # 8H11 creates a fresh product to cross-sell to existing customers and attract new labs focused on HIV assay development and sensitive diagnostic workflows.

Quality Leadership Appointment of a new Head of Quality and Compliance and a long-tenured predecessor’s departure highlight a strong emphasis on regulatory readiness and quality assurance, which can reassure buyers prioritizing validated reagents and compliant supply chains.

Product Portfolio Growth Recent recombinant RD15 launch and broad antibody/antigen offerings across cardiac, infectious, neuroscience, and autoimmune areas present multiple cross-sell and up-sell pathways to IVD developers and research labs.

Scale & Revenue With revenue in the high hundreds of millions and a clear focus on expanding commercial infrastructure, there is an opportunity to target larger lab networks, CROs, and regional distributors for scalable partnerships and larger purchase commitments.